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Behcet’s disease (BD) is a rare relapsing systemic inflammatory disorder with a chronic, relapsing-
remitting course of unknown etiology, current knowledge suggests that BD could follow an autoimmune 
process triggered by an infectious or environmental agent in genetically predisposed individuals. BD has 
been hallmarked predominantly by oral aphthosis, genital ulcers, and chronic relapsing bilateral uveitis, 
all of which represent the “stigmata” of disease. However, many other organs including the vascular, 
neurological, musculoskeletal, and gastrointestinal systems can be affected. BD occurs most frequently 
in Eurasian populations along the ancient trading route known as the “Silk Road” which extends from 
eastern Asia to the Mediterranean basin. The diagnosis of BD is only supported by clinical criteria and 
requires the exclusion of other diagnoses based on clinical presentation. There are no pathognomonic 
laboratorial findings of BD. This rare disease often leads to blindness and fatal systemic involvement. 
Main causes of death include major vessel disease and central nervous system involvement. 
Corticosteroids are commonly used to treat clinical manifestations of BD in combination with 
immunosuppressant drugs. Tumor necrosis factor (TNF)-blocking agents such as Infliximab, Etanercept, 
and Adalimumab have been reported to have success in patients with BD.   
Keywords: Behcet’s disease, auto-inflammatory, systemic vasculitis, Infliximab. 
 
1. Introduction 
          Behcet disease (BD) was initially discovered by a Turkish dermatologist Hulusi 
Behçet in 1937 who identified three patients with oral and genital ulcerations, uveitis, 
and erythema nodosum. Many physical symptoms were later described, and added to 
the spectrum of disease [1]. BD is an auto-inflammatory systemic vasculitis of obscure 
etiology. Recurrent oral ulcers, genital sores, and ocular lesions usually used to 
characterize BD; however many other organs including the vascular, neurological, and 
musculoskeletal systems as well as the gastrointestinal system can be involved. In 
addition, this disease is also known as Behçet syndrome and malignant aphthosis [2-4]. 
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2.  Epidemiology 
Behcet disease usually has an onset in the third decade of life and is rare before 
puberty or after 50 years of age. It is believed that BD affects more males than females, 
in a proportion that varies from (1.5-5:1), and is in general more serious in male 
patients. However, a series of western studies (which included Brazilian studies) 
revealed a female predominance, but with less intense manifestations. Factors that 
modulate this clinical expression are still unknown [5]. A male predominance is 
observed in Arab populations while female predominance is evident in Japan, Korea, 
China, the United States, and some northern European countries. The disease has a more 
severe course in males and younger population. [6-10]  BD has significant regional 
differences, with highest incidence in the Mediterranean, the Middle East, and the Far 
East [11]. The association of BD with the ancient trading route known as the “Silk 
Road” which extends from eastern Asia to the Mediterranean basin and the distribution 
of HLA-B5 and its HLA-B*51 subtype provides important clues to its origin. BD occurs 
most frequently between the latitudes 30° and 45°Nin Eurasian populations. Global 
distribution of BD is schematized in Figure(1) [12-14]. The incidence of BD varies 
according to geographical location, and does not follow Mendelian rules as shown by 
family studies [13]. The highest prevalence is found in Turkey, with up to 420 per 
100,000 persons affected. Iran, Israel, northern China, and Korea follow with the next 
highest prevalence [14]. The countries with the lowest prevalence are the United 
Kingdom, Spain, Sweden, Portugal, and the United States, ranging from 0.3 to 6.4 per 
100,000 persons [15,16]. The prevalence of BD have been reported (per 100 000 
inhabitants) to be 13.5 in Japan [17]; 19.5 in Saudi Arabia, 15.2 – 120/100 000 in Israel, 
2.1/100 000 in Kuwait, 17 in Iraq and 7.6/100 000 in Egypt [18]; 80 in Iran [19], 14 in 
China [20], Within Europe, the reported prevalence (per 100 000 inhabitants) trends 
higher among people in the Mediterranean area; Italy 2.5, Spain 7.5 and France 2.4 
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Figure (1): Global distribution of Behçet's disease [14]. 
 
3. Etiopathogenesis 
        BD has unknown causes; current knowledge suggests that BD could follow an 
autoimmune process triggered by an infectious or environmental agent in genetically 
predisposed individuals [23]. 
3.1 Genetic   
      Four aspects demonstrate the genetic influence on BD susceptibility: peculiar 
geographical distribution, familial aggregation, correlation with HLA-B51 class I 
antigen, and polymorphisms in genes that control immune responses. HLA-B51 allele 
located in the major histocompatibility complex (MHC)  locus on chromosome 6p has 
been the most strongly associated risk factor for BD in areas along the Old Silk Route; 
a stronger association has been described in Turkish and Japanese patients compared to 
Caucasians [12]. Studies have shown that HLA-B*51 is associated with BD, with more 
than 60% of patients testing positive for HLA-B*51[24]. 
          Other genes present in the MHC locus have been studied like HLAB5701, 
Associated with disease susceptibility and MICA (MHC class I related gene) and TNF 
genes; however, their participation is considered to be due to linkage disequilibrium 
with HLA-B51 gene [25]. 
Several other genes located outside the MHC region have been proposed to be involved 
in BD pathogenesis. Meta-analyses identified that common variants of the IL10 and 
encoding interleukin 23 receptor (IL23R) and encoding interleukin 12 receptor beta 
(IL12B2) genes were strongly associated with BD [26]. IL23 is a proinflammatory 
cytokine that stimulates Th17 proliferation, increases the production of inflammatory 
cytokines, and increases the expression of IL-23 p19 mRNA in erythema no do sum-
like skin lesions in patients with active BD [27]. IL10 is known as an anti-inflammatory 
cytokine that inhibits the action of proinflammatory cytokines, and the up-regulation of 
the CD4+ CD25+ T-regulatory cells in a BD-like mouse model improved the 
inflammatory symptoms via IL10 [28]. Therefore, the IL10 and IL23R-IL12B2 genes 
may play major roles in the pathogenesis of BD. Factor V gene, also called factor V 
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Leiden (FVL), have been associated with thrombosis and ocular involvement in BD 
with controversial results [29]. Recently, the study of [30] was reported that a high 
percentage of patients with BD have one or several variants in AID genes. Additionally, 
they suggest that the association of MEFV with BD could be modulated by the HLA 
molecules; whereas the protective effect of the loss of function of NOD2 p.Arg702Trp 
polymorphism would be independent of HLA. Behcet’s disease has been shown to be 
associated with genotoxicity as measured by cytogenetic and oxidative DNA damage 
assays. For example, elevation in sister chromatid exchange (SCE) in BD lymphocytes 
has been shown by several reports [31]. The increase in the SCE rate was evident in 
patients with active and inactive episodes and in patients typed positive or negative for 
HLA-B51allele. The mechanism for this genotoxicity is still not clear, however, 
significant elevation in the oxidative damage biomarkers such as 8-hydroxy 
deoxyguanosine, plasma malondialdehyde and protein carbonyl was detected in BD 
patient’s [32]. In addition, levels of ascorbic acid and antioxidant enzymes that include 
catalase, glutathione peroxidase and superoxide dismutasewere relatively lower in BD 
patients than in healthy controls [33].  
 
3.2 Infection 
          Infectious agents have long been proposed as triggering factors in BD 
development. A number of bacterial and viral microorganisms have long been 
postulated as possible environmental triggers of BD, specially Herpes simplex virus-1 
and Streptococcus Sanguis [12,34]. The most commonly investigated microorganism 
in the pathogenesis of BD is Streptococcus. The relationship between streptococcal 
infections and BD is suggested by clinical observations such as a higher incidence of 
infections such as tonsillitis and dental caries, aggravation of BD and the beneficial 
effect of antibacterial treatments on mucocutaneous and arthritic symptoms [35]. 
Several Streptococcus strains have become increasingly important in infectious 
etiology. The development of some clinical manifestations of the disease in 
hypersensitivity tests against streptococcal antigens is one of the most relevant 
evidences [36]. In addition, antibodies against S. sanguinis and S. pyogenes were 
obtained more frequent in BD patients than in controls [37]. Streptococcal 65-kDa HSP 
from an uncommon serotype (KTH-1, strain BD113-20) of oral S. sanguinis has been 
reported to be an important trigger in the pathogenesis [14]. Neurofilament medium 
(Nf-M) was recently suggested as possible antigen able to trigger an immune response 
via molecular mimicry with bacterial HSP-65 [38]. Immunoglobulin M in BD patients 
has been reported able to react with some streptococcal proteins such as streptococcal 
a-enolase and glyceraldehyde 3-phosphate dehydrogenase [39]. Cho et al. demonstrated 
that the S. sanguinis GroEL protein is a target of the serum anti-S. sanguinis IgA 
antibody. In addition, serum IgA reactivity against recombinant S. sanguinis GroEL has 
been correlated to reactivity against recombinant human hnRNP A2/B1 suggesting how 
autoreactive lymphocytes may be activated by infectious triggering [40]. As BD usually 
starts from the oral mucosa, it has been speculated that oral microbial flora may be 
implicated in the pathogenesis of the disease [41]. BD patients can develop newonset 
oral ulceration or experience both cutaneous and systemic flare-ups following dental 
 
Journal of University of Babylon for Pure and Applied Sciences, Vol. (28), No. (2): 2020   




© Journal of University of Babylon for Pure and Applied Sciences (JUBPAS) by University of Babylon is licensed under a Creative 
Commons Attribution 4. 0 International License, 2020. 
https://www.journalofbabylon.com/index.php/JUBPAS, info@journalofbabylon.com, jub@itnet.uobabylon.edu.iq 




procedures or surgical treatments for chronic tonsillitis [42]. Antimicrobial agents have 
been used successfully for treating various disease symptoms [43]. Several previous 
studies and our experience showed oral health impairment in BD patients compared 
with healthy subjects [44,45]. Oral health improvement in BD patients may positively 
modify their disease course. Dental treatments in BD patients could be associated with 
a relapse of oral aphthae in the short time but could decrease their number in longer 
follow-up (_6 months) [46], also leading to better oral health in the long-term follow-
up. Higher levels of various Streptococci were found in the oral mucosa of BD patients. 
In addition, S. sanguinis strain resulted able to induce the secretion of inflammatory 
cytokines by the KTH-1 cells. It is plausible that an inflammation process induced by 
infectious agents in subjects with predisposing genetic background leads to the 
development of BD [47,48].  Several studies have investigated the association between 
HSV-1 and BD. Herpes Simplex Virus (HSV) type 1 can be detected in saliva, intestinal 
ulcers, and genital ulcers by polymerase chain reaction (PCR) in patients with BD 
compared with healthy controls [49,50]. In addition, a BD-like mouse model was 
developed by inoculation of mouse earlobes with HSV and demonstrated HSV DNA 
sequences in cutaneous and gastrointestinal ulcerative lesions [51]. Studd et al. in an 
situ DNA-RNA hybridization method, detected a higher frequency of hybridization 
between HSV-1 DNA and complementary RNA in mononuclear cells of BD patients 
compared with healthy controls. The results show the presence of at least a portion of 
the HSV-1 genome in mononuclear cells of BD patients [52]. Cytomegalovirus, 
Epstein-Barr virus, Parvovirus B19, Varicella zoster virus, Hepatitis virus have also 
been investigated as possible triggering factors but these studies were characterized by 
low-level evidences [53,54]. Recent studies have shown that the differences in salivary 
or gutmicrobiome compositionmay have a role in the pathogenesis. In a study of the 
salivary microbiome using high- throughput sequencing of the 16S rRNA V4 region, 
Coit et al. reported that BD patients have a significantly less diverse microbial 
community structure than healthy controls [55]. In another study, Consolandi et al. 
compared the fecal microbiota of BD  patients to healthy controls. They reported both 
a peculiar dysbiosis of the gut microbiota and a significant decrease of butyrate 
production in BD patients. Authors speculated that a defect of butyrate production 
might lead to both reduced T regulatory cells (Tregs) responses and activation of 
immunopathological T-effector responses [56]. To date, the most generally accepted 
theory to explain the effect of infectious agents in BD is the high homology that some 
microorganism antigens may have with human proteins, such as that of heat shock 
protein (HSP 65) obtained from Mycobacterium, with human protein (HSP60); this 
cross-reaction may lead to the onset of an immune response [57]. Research on genes 
related to apoptosis have not shown conclusive results.  
 
3.2  Immunity 
       Autoimmune reactions in BD are suggested to target primarily blood vessels, 
especially endothelial cells, causing the clinical presentation of vasculitis. Anti-
endothelial cell antibodies (AECA) have been described in many vasculitides, including 
BD, thus linking their presence to the pathogenesis of the condition [58]. Lee, et al. [59] 
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identified α-enolase as a target antigen of IgM-type AECA in patients with BD using 
proteomic techniques. Several mechanisms were proposed in order to explain the action 
of AECAs in the pathophysiology of inflammatory diseases, including the binding of 
AECA to endothelial cells resulting in cell activation, which may in turn increase 
secretions of cytokines. AECAs might also trigger inflammatory processes by 
complement-dependent cytotoxicity and/or antibody-dependent cellular toxicity[14]. 
Activated innate immunity plays an important role in the pathogenesis of BD. Microbial 
triggers are sensed and processed by the innate immune system via pathogen-related 
and/or danger-associated molecular patterns. Overproduction of inflammatory 
cytokines by innate immune cells such as macrophages and dendritic cells may cause a 
higher production of adaptive Th1- and Th17-related cytokines. BD lesions in their 
early stages are predominated by neutrophils which have a predominant role in the 
innate immunity system, and abnormalities in their activity have been extensively 
reported in BD patients.  The priming state of neutrophil has been reported in vivo 
among BD patients, and the role of T cells in the neutrophil activation has been shown 
in experimental studies. Elevate concentrations of proinflammatory cytokines including 
IL8, INF γ and TNFα may be responsible for the prime state of neutrophils [60]. IL-8 
is produced by T cells and is a major chemokine known to activate leukocytes, it was 
assumed to represent a link between immune system activation and endothelial 
alteration in BD. Elevated levels of IL8 were reported in serum of BD patients, as well 
as in skin lesions and small vessel endothelial cells, correlating IL8 with disease activity 
and vascular involvement [61,62]. Neutrophil are directly involved in specific lesions 
of BD as histopathological analysis of BD lesions showed venous and arterial infiltrates 
of neutrophils. On the basis of this evidence, it has been proposed to classify BD. 
Surface molecules, indicating neutrophil activation status (CD10,CD14, and CD16), 
oxidative burst and phagocytic function of neutrophils have been explored and the 
presence of proactive neutrophils in BD patients was reported [63]. Tissue injury in BD 
can be modulated by neutrophils in several manners: neutrophils were hyperactivated, 
probably HLA B_51-associated, and usually were involved in perivascular infiltration 
[64].  Recently, Yavuz et al. reported that testosterone causes a significant neutrophil 
activation together with Th-1 type immune alterations which may explain a more 
aggressive disease with a higher mortality rate in male BD patients [65].  
Another member of innate immunity, natural killer (NK) cells are also found in 
BD lesions [66]. NK cells were also identified in BD lesions where seems they have a 
role in driving the CD4+ Th1 response which is the main feature of BD lesions [67,68]. 
However, several studies underlined increased NK cells in the peripheral blood, in 
particular during the active phases of the disease [69,70]. Dysregulation of the immune 
system contributes to BD etiopathogenesis, with increased systemic levels of 
inflammatory cytokines [69]. T cell subpopulations  γδT cells and cytotoxic T cells, 
Th1 T cells, regulatory T cells (Tregs) and Th17 cells have been shown to have a role 
in the pathogenesis of BD [71]. γδ T lymphocytes act as the first line of host defence in 
mucosal immunity. An increased proportion of activated γδ T cells has been shown in 
BD [72,73], suggesting a role for them in the pathogenesis of the disease [74]. 
Furthermore, accumulation of γδ T cells in the sites of inflammation in BD has been 
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reported [75]. It’s well known that CD4+T cells can differentiate into two types: Th1 
cells subset, which secretes IFN-g, IL-2, and TNF and promotes cell-mediated 
immunity, and Th2 cells, which produce IL- 4, IL-5, IL-10, and IL-13 and promote 
antibody-mediated immunity [76]. The alteration of T cell balance, especially 
Th1/Th17 expansion and decreased regulation by Tregs, are supposed to have a 
significant role in BD pathogenesis [77,78]. In particular, increased frequencies of Th17 
cells were reported in the BD cutaneous lesions [79]. Th17 and IL-17 pathways might 
have a part in the development and/or activity of BD [80]. IL-17 levels of BD patients 
with active stages of uveitis, oral and genital ulcers and articular symptoms were 
significantly higher compared with patients with inactive stages of the same symptoms. 
Hamzaoui et al. demonstrated that the percentage of circulating Th17 cells and plasma 
interleukin IL-17 levels were increased in active BD [81,82]. Takeuchi et al. compared 
the proinflammatory and Th1-, Th2-, and Th17-related cytokines frequency in a group 
of BD patients with recurrent uveitis and a group of remitted uveitis before and after 
infliximab treatment. They found higher levels of IL-1b, IL-4, IL-17A, IL-17F, IL-21, 
IL-22, IL-31, IFN-g, sCD40L, and TNF-a, with a significant difference for IL-17F, in 
BD recurrent uveitis patients respect to the BD-remitted uveitis group, before drug 
infusion. In addition, only IL-10 levels were found higher in the remission group than 
in the other group [83]. Emmi et al. showed that cytotoxic Th1 and Th 17 cells can  play 
a role in inducing mucosal damage during the early stages in BD patient with active 
intestinal involvement [84]. These results confirm that Th17 and IL-17 pathway are 
active and play an important role, particularly in acute attacks of the disease. 
Conversely, a reduction in Tregs and cytokine IL-10 were notified in the disease [85]. 
Due to recent progress in molecular methods and basic scientific researches, our 
knowledge about the disease has considerably increased. GWAS have become a very 
important step in understanding BD pathogenesis. New genes such as ERAP1 have 
been introduced which help to understand the possible pathogenic mechanism of HLA-
B_51. In the future, similar studies in different populations with a higher number of 
patients will provide significant advances in the etiopathology of BD. Despite all these 
advances, clinical expression of the disease is quite heterogeneous and show regional 
differences. The underlying environmental and genetic factors of this situation are not 
fully elucidated. Being a complex disease, BD is related more than one pathogenic 
pathway. Although, management of the disease has evolved noticeably because of more 
effective and targeted therapies we still need new treatment options for severe and non-
responsive cases such as biological treatments developed for the underlying 
etiopathological mechanism [86].  
 
4. Diagnosis  
         At least two “major” signs of the disease should be present to make the diagnosis. 
These major signs include aphthous-like ulcerations of the oral mucosa, genital 
ulcerations, and uveitis [87]. Other clinical manifestations that may present through the 
course of the disease include audiovestibular, cardiovascular, pulmonary, 
gastrointestinal, central nervous system, dermatological and joint disorders. As there 
are no pathognomonic clinical or laboratorial findings of BD, several diagnostic criteria 
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have been developed during the years, all having in common the 3major features of oral 
ulceration, genital ulceration and eye lesions. In 1985 during the Fourth International 
Conference on BD, in London, an International Study Group (ISG) for BD was created, 
in order to create a set of criteria for the diagnosis of BD that could be used in the future. 
These ISG criteria were published in 1990, considering diagnosis of BD when recurrent 
oral ulcers plus 2 other features are present, in the absence of other clinical explanations 
[88]. The pathergy test is the non-specific hyper activity of the skin following minor 
trauma and is a unique feature of BD [89]. It consists of the intradermal puncture of the 
skin with a 20-gauge or smaller needle 5mmobliquely into the patient's flexor aspect of 
the avascular forearm skin under sterile conditions and without injecting saline. It is 
considered positive when an indurated erythematous small papule or pustule forms 
within 48 h. Positivity of the test varies with geographical location, being positive in 
more than 60% of Middle Eastern patients, in 15% of Korean patients and in about 5% 
of Caucasian, which considerably reduces its diagnostic values in populations with low 
positivity [90,91]. A study demonstrated that surgical cleansing of the skin before the 
puncture reduced the test positivity [92]. Differential diagnosis plays a relevant role in 
BD.  BD diagnosis is only supported by clinical criteria that require the exclusion of 
other diagnoses based on clinical presentation. Oral ulcerations may occur in 30–40% 
of the general population, and therefore cannot be considered specific of BD; in 
contrast, bipolar ulcerations are more specific of BD. Oral ulcerations may also be 
associated with hemopathy, HIV, Crohn's disease, lupus, bullous dermatosis or vitamin 
deficiencies. Sarcoidosis, Crohn's disease, Vogt-Koyanagi Harada [93] and Cogan 
syndrome [94] must be ruled out in case of ocular involvement. Venous involvement 
should exclude the antiphospholipid syndrome, or thrombophilia. Arterial lesions of 
BD may mimic Takayasu's arteritis or polychondritis. Neuro-BD is sometimes difficult 
to distinguish from multiple sclerosis or Susac syndrome [95]. Lastly, chronic 
inflammatory bowel disorders must be ruled out in case of gastrointestinal involvement 
[96]. When audiovestibular symptoms are present we must consider differential 
diagnosis with SSHL [97] and Meniere's disease [98]. 
 
5. Management  
         Treatment options depend on the affected organ and its severity. It is important to 
prioritize therapeutic options according to the disease type, severity, age, and sex of 
each patient. Special attention should be paid to ocular, vascular, and neurologic 
disease, because they are the most serious manifestations and require more aggressive 
treatment. 
 
 Corticosteroids  
        Topical corticosteroids are beneficial for oral and genital ulcerations, and can be 
the first-line treatment, especially for patients with mild disease, while systemic 
corticosteroids are the recommended treatment for patients with moderate to severe 
disease with ocular, vascular, gastrointestinal, or neurological involvement [99] 
Although corticosteroids are widely used for patients with Behçet’s disease, there has 
been only one placebo-controlled trial, in which 86 patients who had active disease with 
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genital ulcer were randomized for administration of either intramuscular 
methylprednisolone 40 mg or placebo every 3 weeks for 27 weeks.  
 
Colchicine  
        Colchicine has been used for the treatment of Behçet’s disease, particularly for 
mucocutaneous disease. The antiinflammatory effect of colchicine has been attributed 
to its disruption of microtubules in neutrophils, thereby inhibiting their migration 
toward chemotactic factors. In one randomized controlled trial, use of colchicine 
significantly reduced the rate of genital ulcers, erythema nodosum, and arthritis 
associated with Behçet’s disease, especially among female patients [100].  
 
Azathioprine 
 Azathioprine is a purine synthesis inhibitor and one of the most widely used 
immunosuppressive medications for Behçet’s disease. In the only placebo-controlled 
trial, 73 patients who had Behçet’s disease with or without ocular involvement, were 
randomly assigned for treatment with either azathioprine (2.5 mg/kg/day), or placebo. 
After 2 years of follow-up, the patients taking azathioprine developed less ocular 
disease and experienced less frequent ocular complications, oral ulcers, genital ulcers, 
and arthritis [101]. A retrospective analysis of 157 consecutive patients with severe 
uveitis (active posterior uveitis or panuveitis) treated with corticosteroids (0.5–1 
mg/kg/day) and azathioprine (2.5 mg/kg/day) revealed that posterior uveitis was 
controlled in 92.9% of patients, of whom 51.6% were complete responders and 41.4% 
were partial responders [102].  
 
Thalidomide  
      Thalidomide was developed in the 1950s as a sedative drug and was withdrawn in 
1961 because of its teratogenic effects. However, it has been rediscovered recently as 
an immunomodulatory drug that suppresses tumor necrosis factor (TNF)-α-induced 
nuclear factor (NF)-κB activation and adenosine triphosphate (ATP)-induced 
interleukin (IL)-1β secretion [103]. By modulating the activity of NF-κB, thalidomide 
can up-regulate the expression of downstream genes involved in the pathophysiology 
of Behçet’s disease. Thalidomide has been reported to be effective in treating patients 
with mucocutaneous lesions [104]. Cyclophosphamide Although a systematic review 
of the Cochrane database concluded that there was not enough evidence to support the 
use of cyclophosphamide in the treatment of Behçet’s disease, particularly the ocular 
manifestations [105], it still can be a choice for life-threatening manifestations.  
 
Tumor necrosis factor-α inhibitors  
Evidence is emerging that anti-TNFα agents are highly effective for patients with 
Behçet’s disease. Among them, infliximab has been most frequently used, mainly for 
refractory ocular Behçet’s disease. Although there have been no controlled trials, a 
considerable number of observational studies have reported that infliximab reduces the 
frequency of uveitis attacks, successfully treats refractory macular edema, and 
improves visual acuity [106]. Only one prospective study from Japan has evaluated the 
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efficacy of infliximab, using 3–5 mg/kg body weight every 8 weeks in patients with 
gastrointestinal disease. In this study, all patients showed improvement of 
gastrointestinal symptoms and disease-associated complications within 4 weeks. 




BD is a complex syndrome characterized by significant heterogeneity of clinical 
manifestations with usually frequent relapses. The etiology of BD is still obscure: it is 
believed to be due to an autoimmune process triggered by an infectious or 
environmental agent in genetically predisposed individuals. As there are no laboratorial 
findings of BD, the diagnosis is only supported by clinical criteria. Nevertheless, a 
careful evaluation of endoscopic findings may help in the diagnostic interpretation, 
whereas the endoscopic biopsy is necessary to confirma histopathologic diagnosis. The 
management of Behçet’s disease has markedly improved, with better use of 
conventional medications and the development of newer agents such as biologics. The 
main goal of treatment should be aimed at avoiding and preventing the feared 
complications of BD that endanger the life of these patients. Despite tremendous 
research success. There are still many gaps that need to be fulfilled, future studies 
should be directed to the possibility of studying the effect of oxidative stress on the 
development of the disease and the appearance of symptoms in patients in addition to 
studying the genetic and epigenetic changes to determine the most important causes of 
BD especially in Iraqi population. 
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غير معروفة االسباب. تقترح  االضطرابات االلتهابية الجهازية النادرة التي تنتشر بمسارات مزمنة متكررةُيعد مرض بهجت من 
الدراسات الحالية ان مرض بهجت ممكن ان يكون بسبب المناعة الذاتية للجسم ضد تجاه بعض العوامل المعدية او العوامل البيئية لدى 
. يتم تمييز المرض غالبا بوساطة التهاب الفم , القرحة التناسلية والتهاب العنبية المزمن ,وكلها تكون االشخاص المؤهلين وراثيا لالصابة
ومع ذلك، يمكن أن تتأثر العديد من األعضاء األخرى بما في ذلك األجهزة الوعائية والعصبية والعضلية الهيكلية للمرض . "بصمة" بمثابة 
متكرر في السكان األوراسيين على طول الطريق التجاري القديم المعروف باسم "طريق  بشكل مرض بهجت والجهاز الهضمي. يحدث
من خالل المعايير السريرية فقط  مرض بهجت الحرير" الذي يمتد من شرق آسيا إلى حوض البحر األبيض المتوسط. يتم تشخيص
وصات مختبرية خاصة بهذا المرض. غالًبا ما يؤدي هذا ويتطلب استبعاد التشخيصات األخرى بناًء على االعراض السريرية. ال توجد فح
المرض النادر إلى العمى واعتالالت جهازية مميتة. تشمل األسباب الرئيسية للوفاة أمراض األوعية الدموية الرئيسية واعتالالت الجهاز 
مع أدوية مثبطة للمناعة. من هجت مرض بالعصبي المركزي. ُتستخدم الكورتيكوستيرويدات بشكل شائع لعالج المظاهر السريرية لـ
  . Adalimumab و Etanercept و Infliximab مثل TNFالعالجات التي سجلت نجاحا في عالج مرض بهجت هو 
 
